Sign In
Buy GLP
$48.63
+0.410 (+0.85%)
At Close: Jul 28, 2026
EMS and BD expand access to GLP-1 therapies in Brazil with semaglutide launch
06:54am, Wednesday, 29'th Jul 2026
Collaboration pairs leadership in pharmaceuticals and advanced drug delivery technology to support a consistent, reliable treatment experience for metabolic disease patients. FRANKLIN LAKES, N.J.
Eli Lilly Just Made a $2.8 Billion Bet That Goes Beyond GLP-1 Drugs
12:15pm, Tuesday, 28'th Jul 2026
Eli Lilly's newest acquisition will expand its neuroscience portfolio. The company is bracing for stiff competition within its core therapeutic areas.
Logistics giants are racing to keep up with healthcare boom as GLP-1s highlight need for cold storage
08:00am, Saturday, 25'th Jul 2026
Shipping and logistics companies are tapping into the growing healthcare market as cold chain and temperature-controlled facilities become more crucial. Those companies are investing millions of dolla
Five Ways to Get the Most from a GLP-1 Medication
10:02am, Friday, 24'th Jul 2026
Kroger Health dietitians share practical guidance for patients navigating weight-management treatment as part of Kroger's new GLP-1 Complete Support Program CINCINNATI, July 24, 2026 /PRNewswire/ -- G
Global Partners LP to Host Second-Quarter 2026 Financial Results Conference Call on August 7, 2026
08:30am, Friday, 24'th Jul 2026
NEWTON, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (“Global Partners” or the “Partnership”) today announced that it will release its second-quarter 2026 financial results before th
West Pharmaceutical CEO Highlights GLP-1 And Biologics Momentum
11:32am, Thursday, 23'rd Jul 2026
West Pharmaceutical Services, Inc. (NYSE:WST) reported better than expected second quarter 2026 earnings. The injectable solutions company reported adjusted earnings of $2.37 per share, beating the co
How Will Eli Lilly's GLP-1 Portfolio Sales Aid Upcoming Q2 Results?
11:15am, Thursday, 23'rd Jul 2026
LLY's blockbuster GLP-1 portfolio takes center stage as investors watch Mounjaro, Zepbound and Foundayo for clues to Q2 growth and outlook.
Botox maker Galderma sees early boost from 'Ozempic face' trend as GLP-1 use climbs, CEO says
06:27am, Thursday, 23'rd Jul 2026
The increasing rate of patients using GLP-1 medications is now boosting growth in Galderma's aesthetics portfolio, CEO Flemming Ørnskov told CNBC on Thursday. About 10% of U.S. adults now report taki
"Deceptive Advertising!" Claims Novo Nordisk in Explosive New GLP-1 Lawsuit Against Eli Lilly.
05:34pm, Tuesday, 21'st Jul 2026
Novo Nordisk has sued rival GLP-1 drugmaker Eli Lilly in federal court, alleging misleading advertising. Novo alleges that Lilly's ads compare a lower dosage of its weight loss drug Wegovy to the high
Novo Nordisk sues Eli Lilly over GLP-1 drug advertising claims
11:24am, Tuesday, 21'st Jul 2026
Novo Nordisk (NYSE:NVO) has filed a federal lawsuit against Eli Lilly, alleging that its rival's advertising campaigns for blockbuster GLP-1 obesity and diabetes drugs mislead consumers about the effe
GLP-1 Titans Clash: Comparing Eli Lilly and Novo Nordisk
11:20am, Tuesday, 21'st Jul 2026
LLY's leadership in obesity drugs, expanding pipeline and stronger growth outlook set it apart as investors weigh it against NVO in 2026.
Novo Nordisk Sues GLP-1 Rival Eli Lilly For Misleading Advertising
09:15am, Tuesday, 21'st Jul 2026
Ozempic drugmaker Novo Nordisk sued rival GLP-1 manufacturer Eli Lilly in federal court Tuesday, accusing the company of using “intentionally selected outdated studies” to curate allegedly mislead
Novo Nordisk sues Eli Lilly over ads comparing GLP-1 medications
08:18am, Tuesday, 21'st Jul 2026
The drugmaker says Lilly isn't including the most up-to-date clinical information about its drugs
Novo Nordisk filed a lawsuit against rival Eli Lilly accusing it of using outdated studies to promote its GLP-1 drugs
07:58am, Tuesday, 21'st Jul 2026
The maker of Ozempic and Wegovy says its competitor is misleading consumers by citing outdated weight-loss data in advertisements.
Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising
07:35am, Tuesday, 21'st Jul 2026
Novo Nordisk filed a lawsuit against Eli Lilly, alleging that its advertising campaigns for its blockbuster obesity and diabetes drugs are designed to mislead consumers about their superior efficacy r
